What is the difference between Acotiamide and Itopride?

Acotiamide (Acotiamide) and Itopride Hydrochloride (Itopride Hydrochloride) are both important gastric motility drugs in the treatment of functional dyspepsia (FD). However, there are significant differences in their mechanism of action, clinical application characteristics, and pharmacological properties, which directly affects patients' medication selection and therapeutic experience. Functional dyspepsia is a chronic gastrointestinal disease with the main symptoms of upper abdominal discomfort, early satiety, gastric bloating and mild nausea. Its pathological mechanisms mainly involve delayed gastric emptying, abnormal gastric motility, imbalance of gastrointestinal nerve regulation and psychosocial factors. Aiming at these pathological characteristics, acotiamide and itopride respectively exert different therapeutic effects.

Acotiamide is a new gastric motility drug. Its main mechanism of action is to improve gastric emptying and gastrointestinal motility by enhancing gastrointestinal nerve signals related to the vagus nerve. It can specifically enhance the tension of the gastric wall and promote pyloric relaxation in the body, making the emptying of food in the stomach more coordinated, thereby alleviating upper abdominal discomfort and early satiety symptoms. Another significant advantage of acotiamide is that it does not rely on direct activation of cholinergic receptors, but rather enhances gastric motility by regulating the release of endogenous acetylcholine. This mechanism of action makes it well tolerated in long-term use and less prone to dependence. In addition, acotiamide also has advantages in improving gastric motility rhythm disorders and can relieve gastric bloating and belching symptoms caused by abnormal gastric motility.

In contrast, itopride is a classic dopamineD2 receptor antagonist and also has cholinesterase inhibitory effects. It mainly blocks the inhibitory effect of dopamine receptors in the gastrointestinal tract and increases the release of acetylcholine, thereby promoting gastric motility and gastric emptying. Itopride is effective in relieving mild gastric dysmotility and delayed gastric emptying, and is especially suitable for patients with anorexia and gastric insufficiency. However, because it directly acts on dopamine receptors, long-term use may cause central nervous system-related adverse reactions, such as the risk of mild mood changes or affected motor coordination, so clinically it is usually recommended to adjust the dosage according to the patient's specific conditions.

From the perspective of clinical application, acotiamide is more suitable for patients with functional dyspepsia whose main symptoms are early satiety, epigastric fullness, and gastric motility rhythm disorders, while itopride is suitable for patients with obvious delayed gastric emptying, decreased appetite, or mild nausea. Acotiamide generally has a rapid onset of action, and patients can feel improvement in symptoms within a few weeks, and the course of treatment can be flexibly adjusted. For itopride, the medication cycle needs to be determined based on the course of the disease and the intensity of symptoms. The course of treatment is usually short to medium-term, and long-term use requires attention to tolerance and potential adverse reactions.

Additionally, there are differences in global launch and accessibility between the two. Acotiamide fromSince its launch in Japan in 2013, it has been mainly approved in Japan, Russia and some Asian countries. In recent years, it has been gradually undergoing overseas registration and production declaration. Itopride has many years of clinical use experience in some countries in Asia, Europe and Latin America. Its generic drugs are relatively abundant and can meet the needs of patients in different regions. This difference in market layout also affects clinical drug selection and medical insurance coverage strategies.

Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322